IART
HealthcareIntegra LifeSciences Holdings Corporation
Key Drivers
- Margin Recovery
- High Leverage
- Tight Coverage
AIAI Summary
IART has shifted from a “problem stock” to a real turnaround candidate, but the key investment call is whether improving margins and positive free cash flow can translate into sustained revenue growth before heavy leverage and the securities-fraud investigation cap the rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Recovery
- •High Leverage
- •Tight Coverage
IART's recent quarter shows a meaningful turnaround in margins and cash flow, but the company remains a high-risk story due to heavy leverage, thin earnings coverage, and weak full-year 2025 profitability.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Range rejection
- •Volatility risk
Over the last month, IART has stabilized and rebounded from a sharp late-July selloff, but it remains volatile and unconfirmed until it decisively clears the $19.25–$19.80 resistance band.
Sharp drop from $19.76 to $16.49 signals a fast sentiment reversal and elevated swing risk
Sentiment & News
Key News Insights:
- •Earnings beat
- •Shareholder probe
- •Momentum strength
Integra LifeSciences beat Q2 expectations with $419M revenue and $0.56 EPS, but a shareholder investigation adds a legal overhang despite recent momentum and value-stock strength.
The earnings release is supportive for the stock, but the investigation may limit upside until legal uncertainty clears
Similar Companies in Healthcare
Other companies in the same sector with AI ratings